| Title |
Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis
|
|---|---|
| Published in |
BioDrugs, August 2012
|
| DOI | 10.2165/00063030-200519050-00005 |
| Pubmed ID | |
| Authors |
David Murdoch, Katherine A. Lyseng-Williamson |
| Abstract |
Subcutaneous recombinant interferon-beta-1a (Rebif) 22 or 44 microg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis. It has shown benefits on outcome measures related to relapses, progression of disability, and magnetic resonance imaging in clinical trials. A significant efficacy advantage for subcutaneous interferon-beta-1a three times weekly over intramuscular interferon-beta-1a 30 microg once weekly was shown at 24 and 48 weeks. The most common adverse events are generally mild and clinically manageable. Considering both direct and indirect comparative clinical trial data, an assessment suggests that subcutaneous interferon-beta-1a 44 microg three times weekly has the best benefit-to-risk values of the available disease-modifying drugs used to treat relapsing-remitting multiple sclerosis. |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 22% |
| Student > Master | 6 | 19% |
| Researcher | 4 | 13% |
| Student > Ph. D. Student | 4 | 13% |
| Other | 3 | 9% |
| Other | 4 | 13% |
| Unknown | 4 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 5 | 16% |
| Neuroscience | 5 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 13% |
| Medicine and Dentistry | 4 | 13% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Other | 5 | 16% |
| Unknown | 7 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2024.
All research outputs
#3,798,287
of 25,371,288 outputs
Outputs from BioDrugs
#120
of 746 outputs
Outputs of similar age
#26,063
of 186,051 outputs
Outputs of similar age from BioDrugs
#27
of 257 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 746 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.5. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,051 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 257 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.